Follicular lymphoma is a slow-growing cancer of the immune system, specifically affecting white blood cells called B lymphocytes. It is one of the most common types of non-Hodgkin lymphoma, and its relatively indolent nature means many people live with it for years or even decades. The five-year relative survival rate is about 89%, based on data from 2016 to 2022.
How Follicular Lymphoma Develops
Follicular lymphoma starts in the lymph nodes, where B cells normally gather in round clusters called follicles. In this cancer, a genetic error causes a piece of one chromosome to swap places with a piece of another. This swap, known as the t(14;18) translocation, places a gene called BCL2 next to a powerful genetic switch that’s normally used to produce antibodies. The result: BCL2 gets permanently turned on.
BCL2’s job is to prevent cell death. When it’s always active, the affected B cells accumulate instead of dying on schedule. They pile up in the lymph nodes, forming the characteristic follicular pattern that gives the disease its name. This error happens early in B cell development, during the process that normally shuffles gene segments to create diverse antibodies.
Common Symptoms
The hallmark of follicular lymphoma is painless, swollen lymph nodes. These enlarged nodes tend to appear in the neck, armpits, or groin, and they often wax and wane in size over weeks or months. That fluctuating pattern can delay diagnosis, since the swelling sometimes seems to resolve on its own before returning.
Only about 20% of patients experience what oncologists call “B symptoms”: drenching night sweats, unexplained fevers, or unintentional weight loss of more than 10% of body weight over six months. Most people feel well at the time of diagnosis. Occasionally, the disease is discovered incidentally during imaging done for another reason, or it shows up as a large mass in the chest that causes no symptoms at all.
How It’s Diagnosed
A definitive diagnosis requires a biopsy of an enlarged lymph node. Pathologists examine the tissue under a microscope and run a panel of staining tests that highlight specific proteins on the surface of the cancer cells. The cells in follicular lymphoma are consistently positive for a protein called CD20, and most also express CD10, BCL6, and BCL2. When the pattern is ambiguous, additional markers can help confirm the diagnosis.
Grading is based on how many large, abnormal cells (centroblasts) the pathologist counts in the biopsy. Lower-grade disease (grades 1 and 2) is more common, making up roughly 70% of cases, and tends to grow slowly. Grade 3 disease, particularly grade 3B, behaves more aggressively and is often treated differently.
Staging and Risk Assessment
Once diagnosed, imaging scans (typically PET-CT) determine how far the disease has spread. Follicular lymphoma is frequently advanced at diagnosis, meaning it involves lymph nodes on both sides of the diaphragm or has spread to the bone marrow. This sounds alarming, but advanced stage alone does not mean the cancer is immediately dangerous, given how slowly it grows.
Doctors use a scoring tool called the Follicular Lymphoma International Prognostic Index (FLIPI) to estimate outlook. It considers five factors: age over 60, advanced stage, low hemoglobin (a sign of anemia), more than four involved lymph node areas, and elevated levels of an enzyme called LDH in the blood. More of these factors present at diagnosis means a higher-risk category, which helps guide decisions about when and how aggressively to treat.
When Treatment Can Wait
One of the most surprising aspects of follicular lymphoma is that many people don’t need treatment right away. For patients with low tumor burden and no symptoms, the standard recommendation is “watchful waiting,” also called active surveillance. This means regular checkups and imaging without chemotherapy or other drugs.
Watchful waiting is not neglect. It’s a deliberate strategy based on decades of evidence showing that starting treatment early in asymptomatic patients doesn’t improve long-term survival compared to waiting until the disease progresses. Some patients remain on surveillance for years before needing any therapy, and a small number never require treatment at all.
Treatment Options
When follicular lymphoma does need treatment, whether because of symptoms, rapid growth, or organ compromise, the backbone of therapy is a targeted antibody called rituximab. Rituximab locks onto the CD20 protein found on the surface of the cancerous B cells and flags them for destruction by the immune system. It’s given as an IV infusion and is frequently combined with chemotherapy for initial treatment.
For patients whose disease returns after first-line therapy, several options exist. A common combination pairs rituximab with lenalidomide, a pill taken at home that boosts the body’s cancer-killing immune cells. Newer bispecific antibodies, which physically connect cancer cells to the immune cells that destroy them, have also been approved for relapsed disease. In a recent large trial, adding one such drug to the rituximab-lenalidomide combination significantly improved outcomes for patients with relapsed follicular lymphoma.
For the small number of patients whose disease keeps coming back after multiple treatments, CAR-T cell therapy is an option. This involves collecting a patient’s own immune cells, genetically engineering them to recognize and attack the lymphoma, and infusing them back. It’s a one-time treatment that can produce durable remissions, though it requires a specialized center and a recovery period of several weeks.
Risk of Transformation
One of the more serious concerns with follicular lymphoma is the possibility that it transforms into a faster-growing cancer, most commonly diffuse large B-cell lymphoma. This happens at a rate of roughly 1% to 3% per year. Over 10 years, the cumulative risk is about 5%. Transformation changes the nature of the disease significantly and requires more intensive treatment, but it remains uncommon for any individual patient in a given year.
Signs that transformation may have occurred include sudden rapid growth of a lymph node, new B symptoms, or a sharp rise in LDH levels. A biopsy is needed to confirm the change. Because of this risk, even patients on watchful waiting are monitored for any shift in the disease’s behavior.
Living With Follicular Lymphoma
Follicular lymphoma is generally considered a chronic, manageable cancer rather than a curable one for most patients. The exception is the roughly 10% to 15% of cases diagnosed at a truly early stage (limited to one or two nearby lymph node groups), where radiation therapy alone can sometimes produce long-lasting remissions.
For the majority with more widespread disease, the pattern involves periods of treatment alternating with periods of remission. Each remission may last years. With each successive generation of therapies improving outcomes, many patients live 15 to 20 years or more after diagnosis, and the trajectory continues to improve as newer treatments enter standard care.